Form 4: Nuvation Bio Director Acquires Stock Options

Nuvation Bio Inc. reports that Director Kathryn E. Falberg acquired stock options on May 21, 2026, with an exercise price of $4.79.

Summary

• Kathryn E. Falberg, a Director at Nuvation Bio Inc., acquired stock options on May 21, 2026.
• The options have an exercise price of $4.79 per share.
• A total of 123,397 stock options were granted.
• These options are subject to vesting conditions, with full vesting occurring on the one-year anniversary of the grant date (May 21, 2026) or the next annual shareholder meeting, provided continuous service is maintained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director, which is a routine event and does not inherently signal positive or negative performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The grant of options indicates a potential for future equity ownership for a key insider.

Risks

• The vesting schedule for the stock options is contingent on the reporting person's continuous service, meaning a departure before vesting would result in forfeiture of unvested options.
• The value of the stock options is directly tied to the future performance and stock price of Nuvation Bio Inc.

Future Outlook

The stock options are exercisable and vest over time, with full vesting on the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continuous service. The options expire on May 20, 2036.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, often used as a long-term incentive to align management's interests with those of shareholders and encourage sustained performance.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with long-term company performance, potentially benefiting shareholders if the stock price increases.
• Employees: While not directly impacted, such grants can be part of a broader compensation strategy that affects employee morale and retention.
• Management: The reporting person benefits from the potential to acquire equity in the company.

Next Steps

• Continuous service by the reporting person through the applicable vesting dates.
• Potential exercise of stock options upon vesting.
• Expiration of stock options on May 20, 2036, if not exercised.

Key Dates

Keywords

Nuvation Bio Inc., NUVB, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, Securities Exchange Act